Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Theodore A, Bass"'
Autor:
Francesco Franchi, MD, Fabiana Rollini, MD, Victor Kairouz, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maaliki, MD, Latonya Been, AAS, Jason Piraino, DPM, Andres M. Pineda, MD, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M. Zenni, MD, Lisa K. Jennings, PhD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://doaj.org/article/b7ea15f9ac70419180a5ce0ec8e4c853
Autor:
Theodore A. Bass, J. Dawn Abbott, Ehtisham Mahmud, Sahil A. Parikh, Jamil Aboulhosn, Mahi L. Ashwath, Bryan Baranowski, Lisa Bergersen, Hannah I. Chaudry, Megan Coylewright, Ali E. Denktas, Kamal Gupta, J. Antonio Gutierrez, Jonathan Haft, Beau M. Hawkins, Howard C. Herrmann, Navin K. Kapur, Sena Kilic, John Lesser, C. Huie Lin, Rodrigo Mendirichaga, Vuyisile T. Nkomo, Linda G. Park, Dawn R. Phoubandith, Nishath Quader, Michael W. Rich, Kenneth Rosenfield, Saher S. Sabri, Murray L. Shames, Stanton K. Shernan, Kimberly A. Skelding, Jacqueline Tamis-Holland, Vinod H. Thourani, Jennifer A. Tremmel, Seth Uretsky, Jessica Wageman, Frederick Welt, Brian K. Whisenant, Christopher J. White, Celina M. Yong
Publikováno v:
Journal of the American College of Cardiology. 81:1386-1438
Autor:
Francesco Franchi, Fabiana Rollini, Gabriel Faz, Jose Ramon Rivas, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Mustafa Wali, Ahmed Nawaz, Gabriel Silva, Zubair Shaikh, Naji Maaliki, Kerolos Fahmi, Latonya Been, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Usman Baber, Roxana Mehran, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. Th
Externí odkaz:
https://doaj.org/article/febf58ad375f48bcb33144fe435a90c7
Autor:
Theodore A. Bass, J. Dawn Abbott, Ehtisham Mahmud, Sahil A. Parikh, Jamil Aboulhosn, Mahi L. Ashwath, Bryan Baranowski, Lisa Bergersen, Hannah I. Chaudry, Megan Coylewright, Ali E. Denktas, Kamal Gupta, J. Antonio Gutierrez, Jonathan Haft, Beau M. Hawkins, Howard C. Herrmann, Navin K. Kapur, Sena Kilic, John Lesser, Lin C. Huie, Rodrigo Mendirichaga, Vuyisile T. Nkomo, Linda G. Park, Dawn R. Phoubandith, Nishath Quader, Michael W. Rich, Kenneth Rosenfield, Saher S. Sabri, Murray L. Shames, Stanton K. Shernan, Kimberly A. Skelding, Jacqueline Tamis-Holland, Vinod H. Thourani, Jennifer A. Tremmel, Seth Uretsky, Jessica Wageman, Frederick Welt, Brian K. Whisenant, Christopher J. White, Celina M. Yong
Publikováno v:
Circulation: Cardiovascular Interventions. 16
Autor:
Martin M. Zenni, Francesco Franchi, Mattia Galli, Andres M. Pineda, Xuan Zhou, Latonya F. Been, Siva Suryadevara, Ghussan Ghanem, Dominick J. Angiolillo, Theodore A. Bass, Andrea Rivas, Daniel Soffer, Awss Shalhoub, Fabiana Rollini
Publikováno v:
JACC: Cardiovascular Interventions. 14:2410-2412
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Tobias Geisler, Lisa K Jennings, Theodore A Bass, Dominick J Angiolillo
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 8(7)
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most studies the antiplatelet agent of choice used in adjunct to a vascular dos
Autor:
Daniel Soffer, Zubair Shaikh, Jose Rivas, Siva Suryadevara, Theodore A. Bass, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Fabiana Rollini, Dominick J. Angiolillo, Naji Maailiki, Andres M. Pineda, Mustafa Wali, Latonya Been, Martin M. Zenni, Francesco Franchi, Ahmed Nawaz, Gabriel Silva
Publikováno v:
JACC: Basic to Translational Science
Visual Abstract
Highlights • Our study supports the feasibility of using rapid CYP2C19 genotyping among both patients with stable and acute coronary syndrome undergoing diagnostic coronary angiography, with intent to undergo ad hoc PCI, in rea
Highlights • Our study supports the feasibility of using rapid CYP2C19 genotyping among both patients with stable and acute coronary syndrome undergoing diagnostic coronary angiography, with intent to undergo ad hoc PCI, in rea
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Tobias Geisler, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Thrombosis and haemostasis. 122(8)
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic disease.
Autor:
Malhar Agarwal, Naji Maaliki, Fabiana Rollini, Theodore A. Bass, Jose Rivas Rios, Siva Suryadevara, Gabriel Silva, Andres M. Pineda, Daniel Soffer, Lisa K. Jennings, Maryuri Briceno, Victor Kairouz, Andrea Rivas, Mustafa Wali, Francesco Franchi, Ahmed Nawaz, Dominick J. Angiolillo, Jason A. Piraino, Zubair Shaikh, Latonya Been, Martin M. Zenni
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Autor:
Patrick Abou Jaoude, Andres M. Pineda, Martin M. Zenni, Dominick J. Angiolillo, Maryuri Briceno, Xuan Zhou, Naji Maaliki, Latonya Been, Francesco Franchi, Theodore A. Bass, Andrea Rivas, Sida Jia, Chang Hoon Lee, Siva Suryadevara, Fabiana Rollini, Daniel Soffer
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 8(5)
Aims Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Ticagrelor reduces ischaemic events compared to clopidogrel, with the greatest risk reduction in patients with both DM and CK